Shares of Oxford Biomedica plc (LON:OXB - Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 344.16 ($4.72) and traded as low as GBX 305.50 ($4.19). Oxford Biomedica shares last traded at GBX 311.50 ($4.27), with a volume of 79,517 shares trading hands.
Oxford Biomedica Stock Performance
The stock has a 50 day moving average price of GBX 310.71 and a two-hundred day moving average price of GBX 342.44. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The company has a market cap of £335.91 million, a price-to-earnings ratio of -2.35 and a beta of 1.09.
Oxford Biomedica (LON:OXB - Get Free Report) last posted its quarterly earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.57)) earnings per share for the quarter. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%. Analysts predict that Oxford Biomedica plc will post -31.0799998 EPS for the current year.
Insider Activity
In other news, insider Heather Preston acquired 11,389 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was acquired at an average price of GBX 324 ($4.45) per share, for a total transaction of £36,900.36 ($50,638.62). 21.17% of the stock is currently owned by company insiders.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Featured Stories
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
